Latest News and Press Releases

Dublin, Feb. 12, 2025 (GLOBE NEWSWIRE) -- The "Eylea Market Opportunities and Strategies to 2033" report has been added to ResearchAndMarkets.com's offering.This report describes and explains the...

Dublin, Feb. 23, 2024 (GLOBE NEWSWIRE) -- The "Aflibercept (Eylea) Biosimilars Pipeline Review" report has been added to ResearchAndMarkets.com's offering.This product provides basic information on...

Exton, Pennsylvania, Feb. 08, 2024 (GLOBE NEWSWIRE) -- As Age-Related Macular Degeneration (AMD) Awareness Month unfolds, illuminating the visual challenges faced by millions of Americans with AMD,...

Appointment of Independent Director Nominee to become effective upon approval by and listing of common stock on a National Exchange Boca Raton, FL, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Curative...

Exton, Pennsylvania, Nov. 01, 2023 (GLOBE NEWSWIRE) -- As U.S. ophthalmologists increasingly embrace a wider array of treatment options, the landscape of the diabetic macular edema (DME) market has...

Dublin, July 25, 2023 (GLOBE NEWSWIRE) -- The "Eylea Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. This report provides strategists, marketers, and senior...

New York, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Anti-Vascular Endothelial Growth Factor Therapeutics market is expected to reach a US$ 455 Mn by 2032 at a CAGR 1% | According PMR Anti-Vascular...

Dublin, June 03, 2022 (GLOBE NEWSWIRE) -- The "Anti-Vascular Endothelial Growth Factor Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Product; By Disease; By Region; Segment...

78% of Patients Required No Additional Treatment in the Trial Arm with Concomitant Suprachoroidally Administered Zuprata™ and Intravitreally Administered Eylea®Patients Reached an Average BCVA...

SAN FRANCISCO, CA--(Marketwired - Jul 31, 2013) - Vista Partners announced today that it has updated coverage on Ohr Pharmaceutical, Inc. (NASDAQ: OHRP) ("The Company" or "OHR") and raised its...